Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Trial Evaluating the Safety and Efficacy of Radioactive Particle and Fluzoparib Combination Therapy in the Treatment of Advanced Unresectable Soft Tissue Sarcoma

NCT05894018 is registered in ClinicalTrials.gov with Fujun Zhang as lead sponsor.

NCT NCT05894018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05894018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Trial Evaluating the Safety and Efficacy of Radioactive Particle and Fluzoparib Combination Therapy in the Treatment of Advanced Unresectable Soft Tissue Sarcoma
Lead sponsor
Fujun Zhang
Phase
Phase 2
Overall status
Recruiting
Start date
June 29, 2023
Completion date
December 31, 2028
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brachytherapy, poly(adp-ribose) polymerase inhibitors, sarcoma,soft tissue